Lynx1 Capital Management LP Kinnate Biopharma Inc. Transaction History

Lynx1 Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $35,616 - $42,294	-15,900 Reduced 0.8%	1,981,106 $5.27 Million
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $71,387 - $171,226	-51,730 Reduced 2.52%	1,997,006 $2.8 Million
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $385,647 - $1.13 Million	-165,514 Reduced 7.47%	2,048,736 $6.21 Million
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $746,782 - $1.72 Million	215,833 Added 10.8%	2,214,250 $13.8 Million
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $1.7 Million - $3.95 Million	323,740 Added 19.33%	1,998,417 $12.2 Million
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $7.3 Million - $12.8 Million	982,169 Added 141.83%	1,674,677 $21.1 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $5.35 Million - $12.5 Million	692,508 New	692,508 $7.8 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.